Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irifaze ICV (idursulfase beta)
- Development stage
- Unknown
- Lead developer
- GC Biopharma
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intrathecal
01
Overview
Irifaze ICV (idursulfase beta) is a recombinant human iduronate-2-sulfatase (IDS) enzyme replacement therapy developed by GC Biopharma. It is specifically formulated for intracerebroventricular (ICV) administration to treat the severe form of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) characterized by central nervous system (CNS) involvement. By delivering the enzyme directly into the cerebral ventricles via an implanted reservoir, the drug bypasses the blood-brain barrier, which typically limits the efficacy of intravenous enzyme replacement therapies in treating cognitive decline. It was first approved in Japan (as Hunterase ICV) and subsequently in Taiwan (as Irifaze ICV), making it a pioneering treatment for the neurodegenerative aspects of MPS II.
- Brand names
- Irifaze ICVHunterase ICV
- Other names
- idursulfase betarecombinant human iduronate-2-sulfatase
02
Targets
IDS (Iduronate-2-sulfatase)IGF2R (Cation-independent mannose-6-phosphate receptor)
Beyond the preview
Go deeper on Irifaze ICV (idursulfase beta).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irifaze ICV (idursulfase beta).